FDA Guidance Will Detail Medicare Rx Law’s Effect On ANDA Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
The pending reference listed drug guidance will include questions & answers about the Medicare law’s Waxman/Hatch reforms, FDA Director of Regulatory Policy Dupont says. The guidance is expected “very shortly.”
You may also be interested in...
Separate ANDAs Are Required For Different Dosage Forms, FDA Guidance Says
The draft guidance includes discussion of the Medicare Modernization Act's effect on FDA generic review processes, including application of 30-month stays and 180-day exclusivity. FDA will not amend its current definition of reference listed drugs, the guidance notes.
Separate ANDAs Are Required For Different Dosage Forms, FDA Guidance Says
The draft guidance includes discussion of the Medicare Modernization Act's effect on FDA generic review processes, including application of 30-month stays and 180-day exclusivity. FDA will not amend its current definition of reference listed drugs, the guidance notes.
FDA “Listed Drug” Definition For ANDA “Bundling” Should Maintain Current Flexibility – GPhA
Generic Pharmaceutical Association says forthcoming agency guidance should embody current practices, which allow ANDA filers to “bundle” different variations of generic products into one application.